LD
CVS icon

Lipe & Dalton’s CVS Health CVS Stock Holding History

Lipe & Dalton’s Portfolio CVS Stock Details CVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.47M Sell
23,870
-495
-2% -$44.2K 1.15% 29
2026
Q1 		$1.75M Sell
24,365
-2,292
-9% -$177K 0.92% 36
2025
Q4 		$2.12M Sell
26,657
-640
-2% -$50.5K 1.04% 32
2025
Q3 		$2.06M Sell
27,297
-100
-0.4% -$6.85K 1.02% 34
2025
Q2 		$1.89M Sell
27,397
-725
-3% -$47.5K 1.02% 38
2025
Q1 		$1.91M Buy
28,122
+920
+3% +$55.1K 1.07% 35
2024
Q4 		$1.22M Buy
27,202
+52
+0.2% +$2.92K 0.65% 44
2024
Q3 		$1.71M Buy
27,150
+200
+0.7% +$11.7K 0.86% 38
2024
Q2 		$1.59M Sell
26,950
-1,315
-5% -$82.3K 0.86% 38
2024
Q1 		$2.25M Buy
28,265
+250
+0.9% +$19.1K 1.16% 31
2023
Q4 		$2.21M Buy
28,015
+270
+1% +$19.2K 1.2% 30
2023
Q3 		$1.94M Hold
27,745
– – 1.17% 31
2023
Q2 		$1.92M Buy
27,745
+12,471
+82% +$887K 1.09% 32
2023
Q1 		$1.14M Sell
15,274
-249
-2% -$20.9K 0.65% 44
2022
Q4 		$1.45M Sell
15,523
-148
-0.9% -$14.3K 0.83% 38
2022
Q3 		$1.5M Buy
15,671
+2
+0% +$198 0.94% 38
2022
Q2 		$1.45M Buy
15,669
+1
+0% +$98 0.85% 39
2022
Q1 		$1.59M Sell
15,668
-45,402
-74% -$4.77M 0.77% 39
2021
Q4 		$6.3M Sell
61,070
-298
-0.5% -$27.5K 2.98% 9
2021
Q3 		$5.21M Buy
61,368
+1,451
+2% +$122K 2.68% 11
2021
Q2 		$5M Sell
59,917
-48
-0.1% -$3.93K 2.6% 11
2021
Q1 		$4.51M Sell
59,965
-328
-0.5% -$23.9K 2.5% 13
2020
Q4 		$4.12M Buy
60,293
+1,427
+2% +$92.8K 2.53% 12
2020
Q3 		$3.44M Buy
58,866
+316
+0.5% +$19.7K 2.39% 16
2020
Q2 		$3.8M Sell
58,550
-98
-0.2% -$6.17K 2.76% 10
2020
Q1 		$3.48M Sell
58,648
-937
-2% -$62.6K 2.94% 13
2019
Q4 		$4.43M Buy
59,585
+1,731
+3% +$122K 2.93% 10
2019
Q3 		$3.65M Buy
57,854
+3,502
+6% +$208K 2.66% 12
2019
Q2 		$2.96M Buy
54,352
+426
+0.8% +$22.9K 2.12% 18
2019
Q1 		$2.91M Buy
53,926
+1,226
+2% +$75.7K 2.14% 17
2018
Q4 		$3.45M Sell
52,700
-197
-0.4% -$14.7K 2.81% 14
2018
Q3 		$4.16M Buy
52,897
+1,396
+3% +$99.8K 2.84% 13
2018
Q2 		$3.31M Buy
51,501
+3,030
+6% +$200K 2.44% 19
2018
Q1 		$3.02M Buy
48,471
+1,505
+3% +$108K 2.16% 22
2017
Q4 		$3.4M Buy
46,966
+545
+1% +$39.6K 2.35% 23
2017
Q3 		$3.77M Buy
46,421
+2,950
+7% +$233K 2.65% 17
2017
Q2 		$3.5M Buy
43,471
+6,700
+18% +$529K 2.27% 20
2017
Q1 		$2.89M Buy
36,771
+34,213
+1,337% +$2.73M 2.09% 24
2016
Q4 		$202K Hold
2,558
– – 0.14% 63
2016
Q3 		$228K Sell
2,558
-700
-21% -$66.1K 0.15% 75
2016
Q2 		$312K Hold
3,258
– – 0.22% 63
2016
Q1 		$338K Sell
3,258
-200
-6% -$19.4K 0.27% 50
2015
Q4 		$338K Hold
3,458
– – 0.27% 47
2015
Q3 		$334K Sell
3,458
-97
-3% -$10.2K 0.28% 51
2015
Q2 		$373K Hold
3,555
– – 0.27% 47
2015
Q1 		$367K Sell
3,555
-416
-10% -$42.1K 0.25% 50
2014
Q4 		$382K Hold
3,971
– – 0.26% 48
2014
Q3 		$316K Hold
3,971
– – 0.21% 49
2014
Q2 		$299K Hold
3,971
– – 0.19% 48
2014
Q1 		$301K Hold
3,971
– – 0.2% 47
2013
Q4 		$284K Sell
3,971
-12
-0.3% -$771 0.19% 48
2013
Q3 		$226K Sell
3,983
-100
-2% -$5.96K 0.17% 53
2013
Q2 		$233K Buy
+4,083
New +$237K 0.19% 45

Other funds holding CVS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Lipe & Dalton's CVS Position: Q2 2026 in Review

Lipe & Dalton reduced its CVS Health (CVS) stake by 2% in Q2 2026, selling an estimated $44.2K and leaving 23,870 shares worth $2.47M. The position accounts for 1.15% of the portfolio, ranked #29.

Lipe & Dalton first reported a position in CVS in Q2 2013 and has held it in 53 quarters since. The position peaked at $6.3M in Q4 2021. 2,061 funds tracked by Wall St. Rank hold CVS as of Q2 2026.

  • Lipe & Dalton held 23,870 shares of CVS Health worth $2.47M as of Q2 2026.
  • Lipe & Dalton sold 495 CVS Health shares in Q2 2026, an estimated $44.2K.
  • CVS Health made up 1.15% of Lipe & Dalton's portfolio in Q2 2026, its #29 holding.
  • Lipe & Dalton first reported a position in CVS Health in Q2 2013 and has held it in 53 quarters since.
  • Lipe & Dalton's CVS Health position peaked at $6.3M in Q4 2021.
  • 2,061 funds tracked by Wall St. Rank held CVS Health as of Q2 2026.

Based on Lipe & Dalton's 13F filing for Q2 2026, filed 14 Jul 2026.